nav-left cat-right

Pan Omics Summit May 21-22,2015 Boston, MA

We invite you to the attend the Pan-Omics Summit, which will take place May 21 – 22, 2015 in Boston, MA at the Hyatt Regency. This summit has four parallel tracks to discuss the developments and challenges in the popular omics areas of epigenomics, metabolomics, functional genomics, and next generation sequencing. Representatives from big pharma, academic institutions, and government research labs will present data on advances in new technology and case studies on therapeutic targets, molecular diagnostics, and integration of complex data.

The Pan-Omics Summit is comprised of 4 parallel conferences:

5th Next Generation Sequencing

  1. Current and Emerging Sequencing Technologies
    II. Metagenomics and the Microbiome
    III. Leveraging Big Data for Biomedical Discoveries and Applications
    IV. Clinical Diagnostic Sequencing
    V. RNA Sequencing
    VI. Single Cell Genomics
    VII. How Information and Technology get into the Clinic

2nd Metabolomics-Advances & Applications in Human Disease

  1. Advances in Metabolite Markers
    II. Metabolite Identification – Targets and Pathways
    III. Computational Approaches to Assessing the Metabolome
    IV. Technological Advances in Metabolomics
    V. Clinical Applications of Metabolomics

Epigenomics & Novel Therapeutic Targets

  1. Transcriptional Regulation
    II. Novel Therapeutic Targets and Discovery
    III. Pre-Clinical to Clinical Drug Development
    IV. New Technological Advances
    V. Epigenomic Biomarkers and DiagnosticsÂ
    VI. Neurological Disorders and Other Diseases

Functional Genomics

  1. Genomic Variation as a Predictor of Protein-protein and Protein Drug Interactions
    II. Molecular Diagnostics & Therapeutic Applications for Complex Diseases
    III. Transcriptome Profiling and Genome Regulation by mRNAs, microRNAs and long noncoding RNAs
    IV. Approaches for Analysis and Integration of Complex Data
    V. Genome Wide Mutagenesis and Phenotypic Analysis
    VI. Challenges in Target Validation
    VII. Prospects for Epigenomic-based Drug Discovery